Inicio › Cáncer de pulmón › Tennessee
Ensayos clínicos de Cáncer de pulmón en Tennessee
58 estudios sobre Cáncer de pulmón buscan participantes en Tennessee.
Ciudades en Tennessee
Texto oficial del estudio (inglés)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Regional One Health, Memphis
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 3
Edades de 18 a 100 · Todos los sexos · Actualizado el 13 nov 2026 · NCT05920356Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Tennessee Oncology, Nashville
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07100080Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- University Cancer Specialists - Alcoa, Alcoa
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04267848A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- SCRI Oncology Partners, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07020221A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- University of Tennessee Medical Center Knoxville ( Site 0082), Knoxville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06312137Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- University of Tennessee Health Science Center, Knoxville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT04198766A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Baptist Cancer Center, Memphis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06793215Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07519655Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT04181060SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute - Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07857616A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Tennessee Oncology Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Baptist Memorial Hospital-Memphis, Memphis
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06119581A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07903415Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- University of Tennessee Medical Center, Knoxville
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06712316A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06835569A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06172478A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT07154290Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Chattanooga
- Research Site, Memphis
- Research Site, Nashville
- y 1 más
ReclutandoFase 2
Edades de 18 a 95 · Todos los sexos · Actualizado el 21 oct 2026 · NCT05061550Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Baptist Medical Center, Memphis
- Tennessee Oncology, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT06162221Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- West Cancer Center & Research Institute, Germantown
- University of Tennessee Medical Center, Knoxville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT06712355Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06293898Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
ReclutandoFase 2
18 Minutes · Todos los sexos · Actualizado el 9 oct 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 oct 2026 · NCT06616584Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- University of Tennessee Medical Center, Knoxville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT07489066Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga - Medical Park II, Chattanooga
- Tennessee Oncology, PLLC - Franklin, Franklin
- y 11 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT07222566The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06625775Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- SCRI Oncology Partners, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06765109A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07127874A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Tennessee Medical Center, Knoxville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06618287Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Tennessee Oncology, PLLC, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07629960Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06343402Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- Vanderbilt-Ingram Cancer Center, Nashville
ReclutandoEstudio observacional
Edades de 18 a 120 · Todos los sexos · Actualizado el 20 ago 2026 · NCT00897117Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- University of Tennessee - Knoxville, Knoxville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05624996A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT05592626Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 ago 2026 · NCT05433142Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- University of Tennessee Medical Center, Knoxville
- Baptist Cancer Center, Memphis
ReclutandoFase 2
Edades de 18 a 70 · Todos los sexos · Actualizado el 26 jun 2026 · NCT04614103A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- Sarah Cannon, SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT04678648De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.